| Outcome Measures: |
Primary: Glucagon / insulin ratio during hyperglycaemic clamp phase (AUCGluc270-390min / AUCIns270-390min), at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days) | Secondary: Glucagon release during hyperglycaemic clamp phase (AUCGluc270-390min; pg/ml*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|First phase glucagon release during hyperglycaemic clamp phase (AUCGluc270-290min; pg/ml*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|First phase insulin release during hyperglycaemic clamp phase (AUCIns270-290min; pmol/l*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Second phase insulin release during hyperglycaemic clamp phase (AUCIns290-390min; pmol/l*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|First Phase glucagon / insulin ratio during hyperglycaemic clamp phase (AUCGluc270-290min / AUCIns270-290min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Second Phase glucagon / insulin ratio during hyperglycaemic clamp phase (AUCGluc290-390min / AUCIns290-390min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Intact proinsulin release during hyperglycaemic clamp (AUCIP270-390min ; pmol/l*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Insulin / proinsulin ratio during hyperglycaemic clamp (AUCIns270-390min / AUCIP270-390min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|C-Peptide release during hyperglycaemic clamp (AUCC-Pep270-390min ; pmol/l*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|C-Peptide/Insulin ratio during hyperglycaemic clamp (AUCC-Pep270-390min / AUCIP270-390min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|M-Value during euglycaemic-hyperinsulinaemic clamp phase (mg/kg*min), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|HOMAIR Index, Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Body Weight (kg), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Fasting Adiponectin (µg/ml), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Fasting Plasma Glucose (mg/dl), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|HbA1C (mmol/mol; %), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|QuantoseTM Score, Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)|Blood Lipids (Triglycerides [mg/dl]; total, HDL, LDL cholesterol [mg/dl]), Pharmacodynamic endpoints, at baseline (Day 0) as well as after Treatment Phase 1 (after 30 days) and after Treatment Phase 2 (after 60 days)
|
